| Prev Close | 8.27 |
| Open | 8.34 |
| Day Low/High | 8.15 / 8.37 |
| 52 Wk Low/High | 4.15 / 10.74 |
| Volume | 21.59K |
| Avg Volume | 38.60K |
| Exchange | NASDAQ |
| Shares Outstanding | 13.32M |
| Market Cap | 114.03M |
| EPS | -0.90 |
| P/E Ratio | 9.84 |
| Div & Yield | N.A. (N.A) |
Latest News
Ratings Changes Today
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ATRO, BLL, CCE, CSII, EGN, EMR, HCI, IMPV, K, MANT, MLCO, MX, OI, RDS.A, RDS.B, TPRE, USCR, WMC Downgrades: CCO, CLF, GCAP, INCY, KMPR, OMCL, OMI, SHEN, SWIR, UEPS Initiations: ORMP Read on to get TheStreet Quant Ratings' detailed report:
Oramed Pharmaceuticals (ORMP) Stock Surges on $50 Million Chinese Licensing Deal
Oramed Pharmaceuticals (ORMP) stock is rising on heavy volume trading on Monday after the clinical-stage pharmaceutical company announced a $50 million licensing deal in China.
3 Stocks Under $10 to Trade for Breakouts
These under-$10 stocks are within range of triggering breakout trades.
3 Stocks Under $10 Triggering Breakout Trades
These under-$10 stocks are within range of triggering big breakout trades.
A Speculative Biotech Catalyst Trade: ORMP
This beaten-down biotech stock could be ripe for a rebound.
5 Stocks With Big Insider Buying
Insiders at these companies have been scooping up shares of their own stock lately.
These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'
Geron, Celldex Therapeutics, Xoma and Cytrx are among the drug stocks losing more than 30% of their value in the past month.
Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Oramed's Oral Insulin Pill Data 'Completely Worthless'
Oramed hyped results from an insulin pill safety study, then made it difficult to find the actual data.
Biotech Stock Mailbag: Cell Therapeutics and the Ariad Hostile React-o-Meter Meltdown
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Biotech Trading 2014 Starts Hot, But Surprise, Last Year Was Even Better
The biotech sector has jumped off to a strong start to 2014, with today's blockbuster move in Intercept Pharma offering a big assist. I know it's ridiculously early to make any sort of definitive judgment, but I wondered how the first days of biotech trading 2014 compared to 2013. Here are the charts:
![[video] Quick Take: Revolutionizing Diabetes Treatment](http://s.thestreet.com/files/tsc/v2008/photos/all-pics/rx/doctor-patient-front-lead.jpg)
[video] Quick Take: Revolutionizing Diabetes Treatment
This biotech company is seeking to revolutionize the treatment of diabetes. Nadav Kidron reviews Oramed's proprietary product.
Seeking to Remake Diabetes Therapy
This biotech company is seeking to revolutionize the treatment of diabetes. Nadav Kidron reviews Oramed's proprietary product.
Oramed Pharmaceuticals Granted Israeli Patent For Its Core Technology In Oral Delivery Of Proteins
Marking a major milestone for the company, Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Awarded Grant By The Office Of The Chief Scientist Of Israel
Oramed Pharmaceuticals Inc. (OTCBB: ORMP) ( http://www.
Oramed Pharmaceuticals Chosen To Present At The XVI International Symposium On Atherosclerosis (ISA2012), (March 25-29, 2012; Sydney, Australia)
Oramed Pharmaceuticals Inc. (OTCBB: ORMP) ( www.
A New Audio Interview Featuring Nadav Kidron, CEO Of Oramed, Is Now At SmallCapVoice.com
SmallCapVoice.com, Inc.
